Previous clinical trials have shown that liraglutide reduced albuminuria,12 which is thought to be a biomarker of microvascular and macrovascular endothelial dysfunction,13 as well as circulating levels of various inflammatory markers, including CRP, TNF‐α and IL‐6 in individuals with type 2 diabetes.14, 15, 16. This evidence concerns the gene IL6 and endothelial dysfunction.